Agilent Technologies Inc (A) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Agilent Technologies Inc (NYSE:A) have earned an average rating of “Buy” from the ten brokerages that are currently covering the stock, MarketBeat.com reports. Ten equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $77.57.

Several research analysts have issued reports on the company. Zacks Investment Research raised Agilent Technologies from a “hold” rating to a “buy” rating and set a $74.00 price target on the stock in a report on Tuesday, August 7th. Deutsche Bank upped their price target on Agilent Technologies from $77.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, August 15th. ValuEngine cut Agilent Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, May 29th. Finally, Morgan Stanley upped their price target on Agilent Technologies from $83.00 to $84.00 and gave the company an “overweight” rating in a report on Wednesday, August 15th.

Shares of NYSE A traded down $0.48 during trading on Friday, hitting $68.85. The company had a trading volume of 1,447,939 shares, compared to its average volume of 1,857,788. The stock has a market capitalization of $21.65 billion, a P/E ratio of 29.17, a P/E/G ratio of 2.33 and a beta of 1.35. Agilent Technologies has a 52 week low of $60.42 and a 52 week high of $75.00. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.00 and a current ratio of 3.62.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Tuesday, August 14th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.04. The company had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Agilent Technologies had a return on equity of 18.61% and a net margin of 6.20%. The firm’s revenue was up 8.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.59 earnings per share. research analysts forecast that Agilent Technologies will post 2.71 earnings per share for the current year.

In other Agilent Technologies news, Director Paul N. Clark sold 2,876 shares of Agilent Technologies stock in a transaction that occurred on Thursday, September 13th. The shares were sold at an average price of $68.60, for a total transaction of $197,293.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Heidi Fields sold 5,482 shares of the business’s stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $67.73, for a total transaction of $371,295.86. The disclosure for this sale can be found here.

Several institutional investors have recently bought and sold shares of the company. Advisors Capital Management LLC grew its holdings in shares of Agilent Technologies by 1.5% during the 2nd quarter. Advisors Capital Management LLC now owns 51,891 shares of the medical research company’s stock valued at $3,209,000 after acquiring an additional 759 shares in the last quarter. SRS Capital Advisors Inc. boosted its holdings in Agilent Technologies by 75.9% in the second quarter. SRS Capital Advisors Inc. now owns 1,791 shares of the medical research company’s stock worth $110,000 after purchasing an additional 773 shares in the last quarter. Brinker Capital Inc. boosted its holdings in Agilent Technologies by 14.2% in the first quarter. Brinker Capital Inc. now owns 6,334 shares of the medical research company’s stock worth $424,000 after purchasing an additional 788 shares in the last quarter. Advisor Partners LLC boosted its holdings in Agilent Technologies by 8.8% in the second quarter. Advisor Partners LLC now owns 9,932 shares of the medical research company’s stock worth $614,000 after purchasing an additional 803 shares in the last quarter. Finally, Bamco Inc. NY boosted its holdings in Agilent Technologies by 2.9% in the first quarter. Bamco Inc. NY now owns 28,808 shares of the medical research company’s stock worth $1,927,000 after purchasing an additional 808 shares in the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.

Read More: Google Finance Portfolio Workaround

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply